Cathie Wood 增加了对生物技术的投资，减少了对科技热门股的持仓，包括 Shopify 和 Palantir（PLTR）
Cathie Wood's ARK Investment Management has increased its stakes in biotech firms, purchasing significant shares in DraftKings and Intellia Therapeutics, reflecting a bullish outlook in the sector. Conversely, ARK has reduced its holdings in tech stocks, including Shopify and Palantir, as part of a strategy to adjust its exposure to high-multiple e-commerce names amid market volatility. The firm continues to show strong interest in biotech investments while fine-tuning its tech portfolio.
ARK Boosts DraftKings and Intellia Positions
Leading the day's activity, ARK purchased 499,483 shares of DraftKings worth $16.46 million, spread across three of its ETFs. This follows a large buy the previous day, showing ARK's growing confidence in the sports betting firm as more states open to online wagering.
ARK also made a strong move in Intellia Therapeutics, acquiring 479,411 shares valued at $7.09 million through two of its funds. The repeated buying signals a bullish outlook on the gene-editing firm, which remains one of ARK's high-conviction biotech bets within the CRISPR space.
In addition, the firm bought 237,961 shares of 10x Genomics worth $3.23 million, showing ongoing interest in biotech names.
Shopify Leads ARK's Latest Round of Tech Stock Sales
On the sell side, ARK trimmed 61,072 shares of Shopify, valued at $10.69 million, continuing its pattern of reducing exposure to high-multiple e-commerce names after recent volatility in the sector.
Other divestments included Ionis Pharmaceuticals (IONS), Palantir, Roblox (RBLX), Roku (ROKU), and Teradyne (TER), with total sale values ranging from $896,000 to $4.1 million. The trades show ARK is fine-tuning its tech exposure in response to changing market moves.
Let's see how these stocks perform using the TipRanks Stock Comparison Tool:
